

A review on Management of Obesity

Abstract:

Obesity is one of the most difficult conditions that primary care physicians face in their profession. Despite the efforts of both patients and professionals, the condition is becoming more common. A multimodal strategy that includes food, physical exercise, and behavioural disorders is required for treatment. Drugs and surgery are also performed to receive desired results. This study summarises the data for each strategy, discusses how **primary care physicians** might best assist obese patients, and offers weight-loss advice.

New weight-loss techniques to treating obesity appear to have a bright future. Current medications have had limited weight reduction impacts in the overall obese population, but customised medicine will have a stronger impact in smaller homogenous subpopulations of obese people. Multiple, complementary route drug combinations have the ability to produce double-digit weight loss in a larger, varied patient group. Furthermore, the advancement of sophisticated subcutaneous delivery technologies has paved the way for the creation of ground-breaking peptide and biologic medicines for the treatment of obesity.

Obesity is a chronic condition that needs lifetime therapy. The BMI, waist circumference, and other risk variables are all measured as part of the obesity evaluation process. Diet and exercise should be part of the management plan. Only sibutramine and orlistat are FDA-approved for long-term usage, so they can be administered to selected individuals **in the USA**. The only alternative that produces persistent and considerable weight loss is bariatric surgery, which should be provided to very obese individuals.

Keywords: obesity, combination therapy, bariatric therapy, exercise

INTRODUCTION :

Obesity is a fast spreading epidemic that raises the risk of illness and mortality across the world. Obesity is thought to be responsible for up to 300,000 fatalities each year in the United States, however this statistic is debatable.

The goal of the project is to conduct a comprehensive assessment of the existing evidence for obesity weight reduction therapies (lifestyle, surgical, and pharmaceutical) in people over 60, adolescents, and children.

Obesity has reached pandemic proportions in the United States. The recognition of obesity as a chronic disease allows for a better understanding of its management. The National Institutes of Health Consensus Conference on Gastrointestinal Surgery for Severe Obesity provides a paradigm for managing the highly obese, including medicinal versus surgical advice based on scientific and outcome data. Primary prevention, nutritional intervention, increased physical activity, behaviour change, and medication are all medical therapies for obesity. Obesity surgery is better known as Metabolic Surgery because it is based on the significant neural-hormonal effects of weight loss surgery on metabolism. Surgery involves a full preoperative examination, risk assessment, and counselling in addition to the surgery itself. (1)

Discussion:

Diets:

A decrease in calorie consumption is required for long-term weight loss and maintenance. Diets, on the other hand, are useless in the long run without behaviour adjustment and ongoing assistance from health specialists. Counseling patients on how to change their behaviour can help reduce fat and calorie consumption. (1)

Drugs:

Until further proof of safety is available, physicians should avoid prescribing medicines which guarantee weight loss for periods longer than proved by FDA. This decision takes place on the fact if the patient will be motivated or not to make commitments for long term diets and exercise changes in his daily lifestyle to lose weight and get into shape.

Appetite Suppressants:

Topiramate and rimonabant have been linked to weight reduction, although the FDA has not yet authorised them for this use.

In a meta-analysis (24-week data from many trials given in abstract form), topiramate, which modifies -aminobutyric acid receptors, was linked to a 6% weight reduction, but it was also linked to a high incidence of unfavourable central nervous system effects (especially paresthesias and loss of taste).

Rimonabant is a cannabinoid-1 receptor blocker that has not yet been licenced for usage in the US. Two big randomised studies have shown success, with one year weight loss of 6-kg. The stated weight reduction may be optimistic because both studies had a large number of dropouts. The rate of mental issues (depression and anxiety) was much greater (almost double) in the rimonabant group than in the placebo group, a result that merits additional examination.(1)

Impairing mechanism of energy absorption:

Orlistat, from the ingested lipids prevent absorption of a fraction of energy. Orlistat has been authorised by the FDA for a two-year period of usage, but insurance may not be able to reimburse it. It's great for people who are diabetic and can handle low fat diet plus who are at risk of getting the disease. Diarrhea and greasy stools are frequent gastrointestinal side effects, although they normally go away with time.

Combination Therapy:

To yet, there has been insufficient research on combining different weight-loss medicines, therefore it cannot be suggested at this time. Incretins are hormones that are secreted after eating and help the pancreatic beta cells secrete more insulin. Many of these hormones have central effects that suppress appetite, and some of them (such as GLP-1) are effective in the treatment of obesity. (1)

Endoscopic enhancement of effects of **Rou-en-Y Gastric Bypass (RYGB)** when weight regain occurs

Weight gain or plateau in RYGB patients may be linked to an increase in the size of the gastric pouch or the outlet that is the Roux jejunal limb's anastomosis. The processes behind the rise in the size of the gastric pouch are unknown; hence, the change in the gastric pouch might be a cause or, perhaps, a result of excessive postprandial food consumption. Endoscopic suturing, such as purse-string suturing, or sclerotherapy, on the other hand, can shrink the outlet and restore weight loss. (2)

SURGERY:

Although the number of people who have bariatric surgery has grown significantly, the operation may still be underutilised. Surgery has not been shown to reduce mortality, and there are no long-term randomised trials to answer this topic. Roux-en-Y gastric bypass, adjustable gastric bands, sleeve gastrectomy, and biliopancreatic diversion are the most frequent metabolic surgical treatments. Preoperative diabetes, hyperlipidemia, hypertension, and obstructive sleep apnea were cured or improved in more than half of the patients.(3)

Exercise:

There is a lack of evidence from randomised studies to support the relevance of exercise in weight management. Observational studies, on the other hand, means that it is important and critical. Many studies for different perspectives have concluded that healthy workouts in all age and genders are linked to less weight gain over years.(1)

Nonexercise Activity Thermogenesis:

contribution to energy expenditure (NEAT) is by resting metabolic rate, the warm ness of the food, and activity thermogenesis which can classified into formal exercise and thermogenesis by non-exercise activity. Except for sleeping, eating, and organised exercise, NEAT refers to all energy expenditure **eg:....** The huge fall in NEAT over the last century has coincided with an equally significant rise in obesity.(1)

Facilitating behaviour change:

Performing challenging cognitive activities, coping with tough emotional circumstances, and repressing thoughts and emotions all make it more difficult to resist temptation a second time. Exercise and sleep both improve self-control, thus the link between obesity and chronic sleep deprivation is not surprising. Instead of the thought of resisting oneself from temptation as a fact of willpower, it should be seen as an obstacle of getting control of where a persons' attention is focused.

Obesity behavioural treatment refers to a collection of ideas and approaches aimed at assisting overweight people in changing their maladaptive eating and exercise behaviours. The components of this strategy are described in this article, as well as the short- and long-term outcomes of therapy and the use of behavioural and pharmacologic treatments in combination. It finishes with a review of options for improving obesity treatment in primary care. The effectiveness of behavioural and pharmacologic interventions is assessed in light of the new obesity management goals, which are to assist overweight people in achieving a healthful weight rather than an ideal one. Weight decreases of 5% to 10% of baseline weight are typically enough to ameliorate weight-related problems such as hypertension, type II diabetes, and dyslipidemia, according to an increasing body of evidence. **It**

is not required to lose weight to gain these benefits, and it is not achievable for the majority of severely obese people. A new objective of behavioural treatment, which will be explored later, is to assist obese people in accepting smaller weight decreases.

(4)

Self-monitoring:

Self-monitoring of behaviour is a crucial part of behaviour change. Several studies have shown that patients who closely control their calorie intake lose a lot of weight. People who keep track of their calorie intake have shown to be 10 kgs fitter and in better shape than those who don't.

Time efficient self monitoring to help with weight reduction is made easy with programs for portable devices which have a feature of calculating calories, steps etc. (5)

Treatment of obesity in older persons:

There were a total of 256 lifestyle intervention papers discovered, with 69 studies satisfying the criteria. After no qualifying trials for medication or bariatric surgery were discovered, the search was widened to include non-randomized research. The research includes four medication trials and 66 surgical studies. A lifestyle intervention's weight reduction efficacy was comparable in older and younger people, with beneficial effects on a variety of critical outcomes, including physical function and cardiovascular indicators. There was a scarcity of data on obesity medications in the elderly.

Bariatric surgery data show comparable weight reduction and type 2 diabetes resolution in older adults compared to younger people, with same or little increased complication rates. Obesity surgery or significant lifestyle changes should not be considered contraindicated solely because of one's age. There is little evidence to support clinical judgments about obesity treatment in the elderly. (6)

The obese, functionally frail older adult has emerged as a new phenotype of frailty due to the increasing incidence of obesity in older populations across the world. The convergence of the obesity pandemic and global greying will probably definitely increase the frequency of this concern. Due to age-related physiologic changes and a lack of consensus on specific criteria and cutoffs, there is uncertainty about the appropriate amount of obesity that should provoke an intervention. Obesity interventions for this group have also been limited due to concerns about negative effects on lean mass, bone mineral density, and perhaps mortality.(7)

Diet-based Interventions:

A number of trials have looked at and proven the benefits of exertion and working out as a big aspect of ways to reduce obesity. Mostly all studies of weight loss in this aspect include both exercise and calorie deficit. One of these alone is not as effective as may be slower to show changes. (7)

Calorie-restricted weight-loss diets :

In calorie-restricted diet vs. exercise research, calorie-restricted diets almost invariably showed greater weight loss than activity-only therapies. As indicated in Researches, exercise regimens with no strict diet aspect will not show promising results, whereas calorie-deficit diet produces average baseline body weight lowering of five percent to 10 percent.

It has several other good effects: Studies found that an exercise program combined with effective weights reduction diet plan was much more effective at decrease in body fat storage with improving cardio metabolism with its pre disposing risk factors to obesity related diseases in the recently done studies.(7)

Higher-protein weight-loss diets:

It is in agreement that the proteins need of aged persons surpass the RDA of 0.8 g protein **per** kg body weight **and day**, with intakes of 1.5 g protein **per** kg body weight **and day** or higher recommended in high-risk settings. Protein taking above the RDA are associated to improved lean mass reservation, The benefits of high-quality (animal) protein for appendicular lean mass retention, grip strength preservation, and a decreased risk of long-term function deterioration have been verified by recent data from the Framingham trial. With age, there's increased resistance to supposed stimulation due to anabolic processes. Although with great researches there is conclusion that with increased protein intake there is counteract the decreased sensitivity to anabolic stimulation of aged muscles. Essential long chain proteins, particularly **containing** leucine, activate the mTOR signaling system and increased proteins synthesizing in muscles, as shown in multiple short-term studies. For optimum protein synthesis in aged muscle, these studies advocate a balancing, ample proteinin take during the whole day.

The so-called "muscle full" phenomenon occurs when proteins being synthesiz**ed** in muscles induced by amino acid inflow can't be activated again, hence balanced protein consumption, in comparison to consuming all the proteins in the evening meal has been linked to improved outcomes.(7)

Weight-loss diets with other nutrient modifications:

Vitamin D deficiency has been linked to decreased muscle mass and strength, as well as impaired balance, gait, and a higher risk of falling. Several investigations show the workings of vitamin D in obese menopause women with low serum 25-hydroxyvitamin D levels. Both groups participated in mild to heavy exercise. There was no diet alone arm in any of the studies conducted. Vitamin D is the second-most-studied nutrient in terms of function, after protein.(7)

Treatment of childhood obesity:

Lifestyle changes, medicines, and bariatric surgery are the three main treatment options. Recent research backs up the effectiveness of lifestyle treatments in the short term, demonstrating that persistent behavioural intervention improves the possibility of a long-term effect lasting up to two years. The latest research and regulatory choices on obesity drugs (such as orlistat, sibutramine, and metformin) are presented. New evidence suggests that bariatric surgery can lead to great mass loss in obese teens, but it can also have negative consequences. An expert panel has released guidelines that change the way people think about increase in weight provide a ground for dealing with it. All recommendations are in comparison to others, and they are given as a whole.

While primary prevention of childhood obesity is critical, there are currently no widely effective techniques available. An emphasis on treatment is especially crucial, given the enormous number of children with increased weight and their risks. A tiered approach is recommended, with an emphasis on early intervention and lifestyle improvements. (8)

Treatment of adolescent overweight and obesity:

Adolescence is a sensitive time for obesity to develop, and adolescent weight has a strong correlation with adult weight. Previous studies of treatment options neglected to distinguish between teenagers and children, ignoring the population's specific characteristics.

Obesity may be improved in the near term with physical excursion and diet plans. Obesity therapies, on the other hand, have a greater effect when used together when compared to their use alone. Psychological therapies, like therapies to test behaviour and cognition, have shown great scope in making the essential life modifications for weight improvement; so, longer-scoped researches and studies are required. Appraising the literature had a number of drawbacks. Comparisons between research are challenging due to variable and different definitions of obesity. Many researches have failed to employ the amount of adipose in the body in the pubertal age to assess pubertal status, or to use exclusively teenage specimen. Despite these limitations, we

conclude that current data suggests that therapies with behavioural and cognition related treatments with food plus physical exercising approaches may help reduce teenage fat, however longer-term researches and data's are needed.(9-15)

CONCLUSION:

For a successful result there should be combining of more than one weight loss tactics and not only using one individually. Many of the methods covered in this research are culminated in the LEARN programme (**Lifestyle, Exercise, Attitudes, Relationships, Nutrition**); it's a self-help approach made for use in health care setting that will help get the patients started on the correct path for them. Consistent physical activity, the creation of relapse prevention techniques, regular follow-ups with their doctors, and support socially and emotionally from their close ones these all help in prediction for maintaining weight, according to behavioural studies all of these weight strategies overlap with each other.

As stated before physical exercise and workout are the most strongest predictors in maintenance of weight. Patients must follow a systematic workout routine and implement NEAT-increasing methods. Identifying relapse triggers and establishing strategies for dealing with them are critical abilities. When dieters believe they have consumed too much energy for the day, they are more likely to relapse. According to studies, this frequently leads to uninhibited eating and significant increases in energy intake. Patients should be warned not to let a single error set off a chain reaction of errors. Excessive alcohol drinking lowers one's ability to resist temptation and is a common cause of behaviour failure. In high-risk eating scenarios, patients should be counselled to avoid alcohol.

REFERENCES:

1. Kissane NA, Pratt JS. Medical and surgical treatment of obesity. *Best Pract Res ClinAnaesthesiol*. 2011;25(1):11-25. doi:10.1016/j.bpa.2011.01.001
2. Camilleri M, Acosta A. Combination Therapies for Obesity. *MetabSyndrRelatDisord*. 2018;16(8):390-394. doi:10.1089/met.2018.0075
3. Kissane NA, Pratt JS. Medical and surgical treatment of obesity. *Best Pract ResClinAnaesthesiol*. 2011;25(1):11-25. doi:10.1016/j.bpa.2011.01.001
4. GggWadden TA, Foster GD. Behavioral treatment of obesity. *Med Clin North Am*. 2000;84(2):441-vii. doi:10.1016/s0025-7125(05)70230-3
5. Thompson WG, Cook DA, Clark MM, Bardia A, Levine JA. Treatment of obesity. *Mayo ClinProc*. 2007;82(1):93-102. doi:10.4065/82.1.93
6. Haywood C, Sumithran P. Treatment of obesity in older persons-A systematic review. *Obes Rev*. 2019;20(4):588-598. doi:10.1111/obr.12815
7. Bales CW, Porter Starr KN. Obesity Interventions for Older Adults: Diet as a Determinant of Physical Function. *Adv Nutr*. 2018;9(2):151-159. doi:10.1093/advances/nmx016
8. Uli N, Sundararajan S, Cuttler L. Treatment of childhood obesity. *Curr Opin Endocrinol Diabetes Obes*. 2008;15(1):37-47. doi:10.1097/MED.0b013e3282f41d6a
9. Tsiros MD, Sinn N, Coates AM, Howe PR, Buckley JD. Treatment of adolescent overweight and obesity. *Eur J Pediatr*. 2008;167(1):9-16. doi:10.1007/s00431-007-0575-z
10. Garg, Mayank, and Sandip Mohale. "Prevalence of Metabolic Obesity Normal Weight (MONW) in Cardiovascular Disease Patients - A Hospital-Based Case Control Study." *JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS* 9, no. 34 (August 24, 2020): 2427–31. <https://doi.org/10.14260/jemds/2020/528>.
11. Hulkoti, Vidyashree S., Sourya Acharya, Samarth Shukla, Sree Karthik Partapa, and Yash Gupte. "In Search of an Ideal Obesity Assessment Tool : Is Body Mass Index Reliable Enough?"

JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 35 (August 31, 2020): 2556–60. <https://doi.org/10.14260/jemds/2020/555>.

12. Rasheed, Aamil, Sourya Acharya, Samarth Shukla, Sunil Kumar, Roopesh Yarappa, Yash Gupte, and Vidyashree Hulkoti. “High-Sensitivity C-Reactive Protein in Metabolic Healthy Obesity (MHO).” JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS 9, no. 7 (February 17, 2020): 443–47. <https://doi.org/10.14260/jemds/2020/100>.

13. Acharya, Sourya, and Samarth Shukla. “Metabolic Healthy Obesity-A Paradoxical Fallacy?” JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH 12, no. 10 (October 2018): OE7–10. <https://doi.org/10.7860/JCDR/2018/36809.12165>.

14. Parwe S, Mohan M, Bhagwat P, Nisargandha M. Effect of Rodhradi Gana Udavartana in the Management of Sthaulya (Overweight) with Special Reference to Obesity. INTERNATIONAL JOURNAL OF LIFE SCIENCE AND PHARMA RESEARCH. 2021 May;11(3):L30–7.

15. Bhonsle A, Parwe S, Nisargandha M. A Comparative Study to Evaluate the Efficacy of Lekhana Basti and Modified Vachadi Gana Basti in Combination with Navaka Guggulu in Sthaulya (Obesity) -A Study Protocol. JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL. 2021;33(30A):154–61.